Last reviewed 2026-05-14 · How we verify

Abiraterone: Treatment D

At a glance

Approved indications

No approved indications tracked.

Common side effects

• fatigue
• Musculoskeletal pain
• Increased Hemoglobin
• Hypertension
• nausea
• Anemia
• Breast Tenderness
• rash
• hot flashes
• cough
• gynecomastia
• pruritis

Key clinical trials

• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer (PHASE1)
• REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (PHASE3)
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (PHASE1, PHASE2)
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer (PHASE1)
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
• Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 (PHASE1)
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies (PHASE1, PHASE2)
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Abiraterone: Treatment D CI brief — competitive landscape report
• Abiraterone: Treatment D updates RSS · CI watch RSS
• Janssen Research & Development, LLC portfolio CI